ReviewCurrent psychiatry reports2018
Advances in Pharmacotherapy of Late-Life Depression.
Review in Current psychiatry reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Comparative efficacy of group versus individual reminiscence therapy for depression in older adults: A network meta-analysis stratified by severity.International journal of nursing sciences · 2026Pooled it
- Effectiveness of late-life depression interventions on functional limitations: A systematic review.International journal of mental health nursing · 2022Pooled it
- Optimizing antidepressant use in geriatric depression: expert consensus from French societies of geriatrics, old age psychiatry, and clinical pharmacy (SFGG, SF3PA, and SFPC).European psychiatry : the journal of the Association of European Psychiatrists · 2026Article
- Association of Blood Cell-Derived Inflammatory Markers with Symptoms and Short-Term Treatment Response in Late-Life Depression.Neuropsychiatric disease and treatment · 2025Article
- Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations.Frontiers in pharmacology · 2025Article
- Depression as an Embodied Experience: Identifying the Central Role of the Body in Meaning-Making and Identity Processes.Qualitative health research · 2023Article
- Late-life depression: Epidemiology, phenotype, pathogenesis and treatment before and during the COVID-19 pandemic.Frontiers in psychiatry · 2023Review
- Altered topological properties of functional brain networks in patients with first episode, late-life depression before and after antidepressant treatment.Frontiers in aging neuroscience · 2023Article
- The sociodemographic characteristics and clinical features of the late-life depression patients: results from the Beijing Anding Hospital mental health big data platform.BMC psychiatry · 2022Observational
- Inhibitory Effectiveness in Delayed-Rectifier Potassium Current Caused by Vortioxetine, Known to Be a Novel Antidepressant.Biomedicines · 2022Article
- Acceptability and effects of tele-delivered behavioral activation for depression in low-income homebound older adults: in their own words.Aging & mental health · 2021Article
- Clinical Neuropsychological Evaluation in Older Adults With Major Depressive Disorder.Current psychiatry reports · 2021Review
- Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression.Frontiers in psychiatry · 2021Article
- Drug safety profiles in geriatric patients with Parkinson's disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis.Journal of neural transmission (Vienna, Austria : 1996) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper reviews recent research on late-life depression (LLD) pharmacotherapy, focusing on updated information for monotherapy and augmentation treatments. We then review new research on moderators of clinical response and how to use the information for improved efficacy. RECENT
findingsA recent review shows that sertraline, paroxetine, and duloxetine were superior to placebo for the treatment of LLD. There is concern that paroxetine could have adverse outcomes in the geriatric population due to anticholinergic properties; however, studies show no increases in mortality, dementia risk, or cognitive measures. Among newer antidepressants, vortioxetine has demonstrated efficacy in LLD, quetiapine has demonstrated efficacy especially for patients with sleep disturbances, and aripiprazole augmentation for treatment resistance in LLD was found to be safe and effective. Researchers have also been identifying moderators of LLD that can guide treatment. Researchers are learning how to associate moderators, neuroanatomical models, and antidepressant response. SSRI/SNRIs remain first-line treatment for LLD. Aripiprazole is an effective and safe augmentation for treatment resistance. Studies are identifying actionable moderators that can increase treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.